Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (554)	1/20/1998 8:05:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 1686

Mike, it seems it's idiopathic, at least in the company's press release of last week's: "We now have four compounds in clinical trials and expect partners to begin clinical trials of two others. Our ongoing studies of AVONEX(R) are designed to support a broader label, both for MS and additional indications. Other compounds in clinical development are LFA3TIP, a potential treatment for psoriasis; CVT-124 for treatment of edema associated with congestive heart failure, and 5c8/CD40 ligand, which we expect to enter Phase II trials this year in ITP (idiopathic thrombocytopenic purpura), lupus and Factor VIII antibody inhibition. We also anticipate that Merck will begin human testing of an anti-VLA4 inhibitor for asthma this spring and that The Medicines Company will begin trials of HIRULOG(R) in angioplasty and acute myocardial infarction. "